George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.24 (6.486%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.82
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Progress with PREtec field trials in Brazil

15 Aug 2019 07:00

RNS Number : 1095J
Plant Health Care PLC
15 August 2019
 

15 August 2019 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

Progress with PREtec field trials in Brazil

 

Plant Health Care®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to provide the following update in relation to the 2018/19 field trials of the PREtec peptide PHC279 for the control of Asian Soybean Rust (ASR) a potentially devastating disease that regularly affects soybean yields in Brazil.

 

Highlights:

- PHC279 significantly improved ASR control of foliar fungicide programmes, even in fields facing heavy disease pressure.

- Up to 16% increase of soybean yields when PHC279 was applied as a seed treatment.

- Up to 45% increase in the effectiveness of foliar fungicide treatments when seeds had been treated with PHC279.

- Plant Health Care is now moving to register and manufacture PHC279 for launch into soybeans in Brazil as a seed treatment for ASR control.

 

Brazil is the world's largest exporter of soybeans, with some 36 million hectares (89 million acres) planted in 2018. One of the challenges of producing soybeans in Brazil is ASR, which is a potentially devastating disease. Growers spent $2.1 billion in 2017 on soybean fungicides in Brazil.

Plant Health Care's PREtec peptides stimulate the plant to defend itself. Derived from natural proteins, these proprietary peptides are a novel, environmentally friendly approach to protecting crops and increasing yields, compatible with mainstream agricultural practice.

The Company has been trialling the lead peptide PHC279 in Brazil since 2017 under various types of applications. In this year's crop, the Company focused on trials where PHC279 was applied as a seed treatment to soybeans. In contrast, the main focus in the previous year was on mixtures with fungicides applied as a foliar treatment by spraying onto the leaves of plants.

In independent trials, carried out by PLANTEC, a major contract research organisation in Brazil, PHC279 significantly improved ASR control of foliar fungicide programmes, even in fields facing heavy disease pressure. Disease control was improved by up to 45% when PHC279 was applied as a seed treatment. In addition, yields of soybeans were increased by up to 16% when compared with foliar fungicide programs alone. These results provide increasing support for the acceptance of PHC279 as a compelling tool to combat ASR.

Based on these positive results, Plant Health Care intends to move forward to commercialise PHC279 in Brazil. The Company intends to seek a fast track product registration and is making plans to produce PHC279 at commercial scale.

Paulo Fedato, Director of Research and Experimentation at PLANTEC, said: "I am very excited to see Plant Health Care continuing with the development of PHC 279. Based on the results seen in PLANTEC's fields I am confident that it will be a great tool to help growers managing the difficult problem of ASR."

Jeff Tweedy, COO of Plant Health Care, said "After two years of trials, we are extremely encouraged with the performance of PHC279 applied as a seed treatment for ASR control. We see this as a valuable technology for the Brazilian soybean growers. This is further demonstration of the value of the PREtec platform and has given PHC the confidence to move forward with the registration and commercialization of this new technology. The Company continues to work with more than six partners, who are testing peptides on many crops around the world, in markets worth more than $5 billion. With the registration of our first peptides progressing in USA and the scale-up of manufacturing started, we look forward to delivering this novel technology directly to markets in USA, Brazil and other countries."

 

For further information, please contact:

 

Plant Health Care plc

Chris Richards, Executive Chairman and Interim CEO Tel: +44 7795 294 300

Jeff Tweedy, COO Tel: +1 919 926 1600

 

Arden Partners plc - Broker and NomadJohn Llewellyn-Lloyd / Dan Gee-Summons (Corporate Finance) Tel: +44 (0) 20 7614 5900

Fraser Marshall (Equity Sales)

 

 

Company website: www.planthealthcare.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAPIMLTMBABBRL
Date   Source Headline
14th Nov 20187:00 amRNSPositive Developments with Harpin
8th Nov 20187:00 amRNSChange of Adviser
5th Nov 20187:00 amRNSHolding(s) in Company
18th Sep 20187:00 amRNSInterim Report ended 30 June 2018
12th Sep 20187:00 amRNSUS Announces Harpin aß Product Launch in Corn
20th Aug 20187:00 amRNSBlock listing Interim Review
30th Jul 20187:00 amRNSUpdate on sugarcane in Brazil
16th Jul 20187:00 amRNSTrading Statement
6th Jun 20182:39 pmRNSHolding(s) in Company
6th Jun 201811:14 amRNSResult of AGM
30th May 20187:00 amRNSGrant of Options
4th May 20185:59 pmRNSHolding(s) in Company
30th Apr 20183:11 pmRNSPublication of Annual Report and Notice of AGM
10th Apr 20187:00 amRNSResults for the year ended 31 December 2017
8th Mar 20187:00 amRNSBlock listing Interim Review
7th Mar 20183:07 pmRNSHolding(s) in Company
7th Mar 20183:06 pmRNSHolding(s) in Company
7th Mar 20183:02 pmRNSHolding(s) in Company
2nd Mar 20185:48 pmRNSHolding(s) in Company
27th Feb 20184:12 pmRNSResult of Placing and Subscription
27th Feb 20187:00 amRNSProposed Placing and Subscription
24th Jan 20187:00 amRNSTrading Statement
12th Dec 20177:00 amRNSNew Technology Update
8th Dec 20174:35 pmRNSPrice Monitoring Extension
6th Dec 20174:40 pmRNSSecond Price Monitoring Extn
6th Dec 20174:35 pmRNSPrice Monitoring Extension
18th Sep 20177:00 amRNSHalf-year Report
21st Aug 20177:00 amRNSBlock listing Interim Review
3rd Aug 20177:00 amRNSHolding(s) in Company
12th Jul 20174:09 pmRNSGrant of options
30th Jun 20173:30 pmRNSHolding(s) in Company
15th Jun 20177:00 amRNSDirector/PDMR Shareholding
8th Jun 20174:35 pmRNSPrice Monitoring Extension
6th Jun 20177:00 amRNSNew Technology Update
31st May 20177:00 amRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSDirector/PDMR Shareholding
22nd May 20177:00 amRNSGrant of options
11th May 201712:50 pmRNSResult of AGM
27th Apr 20177:00 amRNSPublication of Annual Report and Notice of AGM
10th Apr 20177:00 amRNSResults for the Year Ended 31 December 2016
5th Apr 20174:49 pmRNSChange of Registered Office
5th Apr 20177:00 amRNSHolding(s) in Company
5th Apr 20177:00 amRNSHolding(s) in Company
20th Feb 20177:01 amRNSDirector/PDMR Shareholding
20th Feb 20177:00 amRNSBlock listing Interim Review
8th Feb 20177:00 amRNSHolding(s) in Company
18th Jan 20177:02 amRNSResearch Update
18th Jan 20177:00 amRNSTrading Statement
19th Dec 20164:40 pmRNSSecond Price Monitoring Extn
19th Dec 20164:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.